Maturitas
Volume 60, Issue 3 , Pages 223-229 , July 2008

Self-reported compliance with osteoporosis medication—Qualitative aspects and correlates

  • Magda Vytrisalova

      Affiliations

    • Department of Social and Clinical Pharmacy, Charles University in Prague, Faculty of Pharmacy in Hradec Kralove, Czech Republic
    • Corresponding Author InformationCorresponding author. Tel.: +420 495067486; fax: +420 495512266.
    • ,
  • Sarka Blazkova

      Affiliations

    • Department of Social and Clinical Pharmacy, Charles University in Prague, Faculty of Pharmacy in Hradec Kralove, Czech Republic
    • ,
  • Vladimir Palicka

      Affiliations

    • Osteocentre, Institute of Clinical Biochemistry and Diagnostics, Charles University in Prague, Faculty of Medicine and University Hospital in Hradec Kralove, Czech Republic
    • ,
  • Jiri Vlcek

      Affiliations

    • Department of Social and Clinical Pharmacy, Charles University in Prague, Faculty of Pharmacy in Hradec Kralove, Czech Republic
    • ,
  • Marketa Cejkova

      Affiliations

    • Department of Social and Clinical Pharmacy, Charles University in Prague, Faculty of Pharmacy in Hradec Kralove, Czech Republic
    • ,
  • Tomas Hala

      Affiliations

    • Osteocentre, Regional Hospital Pardubice, Faculty of Medical Health Care, University Pardubice and SYNARC/CCBR Czech, Center for Clinical and Basic Research, Pardubice, Czech Republic
    • ,
  • Karel Pavelka

      Affiliations

    • Institute of Rheumatology, Prague and Department of Rheumatology of the First Faculty of Medicine, Charles University in Prague, Czech Republic
    • ,
  • Helena Koblihova

      Affiliations

    • Department of Social and Clinical Pharmacy, Charles University in Prague, Faculty of Pharmacy in Hradec Kralove, Czech Republic

Received 1 April 2008 ,Revised 30 June 2008 ,Accepted 2 July 2008.

References 

  1. Johnell O, Kanis JA. An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos. Int. 2006;17:1726–1733
  2. Lips P, van Schoor NM. Quality of life in patients with osteoporosis. Osteoporos. Int. 2005;16:447–455
  3. Johnell O, Kanis JA, Odén A, et al. Mortality after osteoporotic fractures. Osteoporos. Int. 2004;15:38–42
  4. Burge R, Dawson-Hughes B, Solomon DH, Wong JB, King A, Tosteson A. Incidence and economic burden of osteoporosis-related fractures in the United States, 2005–2025. J Bone Miner. Res. 2007;22:465–475
  5. Caro JJ, Ishak KJ, Huybrechts KF, Raggio G, Naujoks C. The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporos. Int. 2004;15:1003–1008
  6. McCombs JS, Thiebaud P, McLaughlin-Miley C, Shi J. Compliance with drug therapies for the treatment and prevention of osteoporosis. Maturitas. 2004;48:271–287
  7. Huybrechts KF, Ishak KJ, Caro JJ. Assessment of compliance with osteoporosis treatment and its consequences in a managed care population. Bone. 2006;38:922–928
  8. Compston JE, Seeman E. Compliance with osteoporosis therapy is the weakest link. Lancet. 2006;368:973–974
  9. Seeman E, Compston J, Adachi J, et al. Non-compliance: the Achilles’ heel of anti-fracture efficacy. Osteoporos. Int. 2007;18:711–719
  10. Reginster JY, Rabenda V, Neuprez A. Adherence, patient preference and dosing frequency: understanding the relationship. Bone. 2006;38(4 Suppl. 1):S2–S6
  11. Martin S, Schneider B, Heinemann L, et al. Self-monitoring of blood glucose in type 2 diabetes and long-term outcome: an epidemiological cohort study. Diabetologia. 2006;49:271–278
  12. Cramer JA, Amonkar MM, Hebborn A, Altman R. Compliance and persistence with bisphosphonate dosing regimens among woman with postmenopausal osteoporosis. Curr. Med. Res. Opin. 2005;21:1453–1460
  13. Recker RR, Gallagher R, MacCosbe PE. Effect of dosing frequency on bisphosphonate medication adherence in a large longitudinal cohort of women. Mayo. Clin. Proc. 2005;80:56–61
  14. Carr AJ, Thompson PW, Cooper C. Factors associated with adherence and persistence to bisphosphonate therapy in osteoporosis: a cross-sectional survey. Osteoporos. Int. 2006;17:1638–1644
  15. Weycker D, Macarios D, Edelsberg J, Oster G. Compliance with drug therapy for postmenopausal osteoporosis. Osteoporos. Int. 2006;17:1645–1652
  16. Emkey RD, Ettinger M. Improving compliance and persistence with bisphosphonate therapy for osteoporosis. Am. J. Med. 2006;119(4 Suppl. 1):S18–S24
  17. National Institute for Clinical Excellence. Bisphosphonates (alendronate, etidronate, risedronate), selective oestrogen receptor modulators (raloxifene) and parathyroid hormone (teriparatide) for the secondary prevention of osteoporotic fragility fractures in postmenopausal women. January, 2005. Available from http://www.nice.org.uk/nicemedia/pdf/TA087guidance.pdf. [last accessed 20 June 2008].
  18. Bayer M, Blahoš J, Broulík P, et al. Doporučené postupy pro diagnostiku a terapii postmenopauzální osteoporózy. Osteol. Bull. 2003;8:8–13
  19. Papaioannou A, Ioannidis G, Adachi JD, et al. Adherence to bisphosphonates and hormone replacement therapy in a tertiary care setting of patients in the CANDOO database. Osteoporos. Int. 2003;14:808–813
  20. Curtis JR, Westfall AO, Allison JJ, Freeman A, Saag KG. Channeling and adherence with alendronate and risedronate among chronic glucocorticoid users. Osteoporos. Int. 2006;17:1268–1274
  21. Solomon DH, Avorn J, Katz JN, et al. Compliance with osteoporosis medications. Arch Intern Med. 2005;165:2414–2419
  22. Hamilton B, McCoy K, Taggart H. Tolerability and compliance with risedronate in clinical practice. Osteoporos Int. 2003;14:259–262
  23. McHorney CA, Schousboe JT, Cline RR, Weiss TW. The impact of osteoporosis medication beliefs and side-effect experiences on non-adherence to oral bisphosphonates. Curr. Med. Res. Opin. 2008;24:707
  24. Vytrisalova M, Kubena A, Vlcek J, Palicka V, Hala T, Pavelka K. Knowledge of osteoporosis correlated with hormone therapy use and health status. Maturitas. 2007;56:21–29
  25. Anonymous. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. World Health Organ Tech Rep Ser. Vol. 843. Geneva: World Health Organisation; 1994.
  26. Pande KC, Takats D, Kanis JA, Edwards V, Slade P, McCloskey EV. Development of a questionnaire (OPQ) to assess patient's knowledge about osteoporosis. Maturitas 2000;37:75–81. http://linkinghub.elsevier.com/retrieve/pii/S0378512200001651.
  27. Gold DT, Silverman S. Review of adherence to medications for the treatment of osteoporosis. Curr. Osteoporos. Rep. 2006;4:21–27
  28. Dezii CM. Persistence with drug therapy: a practical approach using administrative claims data. Manage. Care. 2001;10:42–45
  29. Rossini M, Bianchi G, Di-Munno O, et al. Determinants of adherence to osteoporosis treatment in clinical practice. Osteoporos. Int. 2006;17:914–921
  30. Gregoire J, Moisan J, Guibert R, Ciampi A, Milot A. Predictors of self-reported noncompliance with antihypertensive drug treatment: a prospective cohort study. Can. J Cardiol. 2006;22:323–329
  31. Horsman J, Furlong W, Feeny D, Torrance G. The Health Utilities Index (HUI): concepts, measurement properties and applications. Health Qual. Life Outcomes. 2003;1:54
  32. Waterhouse DM, Calzone KA, Mele C, Brenner DE. Adherence to oral tamoxifen: a comparison of patient self-report, pill counts, and microelectronic monitoring. J Clin. Oncol. 1993;11:1189–1197
  33. Lu M, Safren SA, Skolnik PR, et al. Optimal recall period and response task for self-reported HIV medication adherence. AIDS Behav. 2008;12:86–94
  34. Hamilton GA. Measuring adherence in a hypertension clinical trial. Eur. J Cardiovasc. Nurs. 2003;2:219–228
  35. Hugen PW, Langebeek N, Burger DM, et al. Assessment of adherence to HIV protease inhibitors: comparison and combination of various methods, including MEMS (electronic monitoring), patient and nurse report, and therapeutic drug monitoring. J Acquir. Immune. Defic. Syndr. 2002;30:324–334
  36. Chan YM, Molassiotis A. The relationship between diabetes knowledge and compliance among Chinese with non-insulin dependent diabetes mellitus in Hong Kong. J Adv. Nurs. 1999;30:431–438
  37. Tettersell MJ. Asthma patients’ knowledge in relation to compliance with drug therapy. J Adv. Nurs. 1993;18:103–113
  38. Alm-Roijer C, Stagmo M, Uden G, Erhardt L. Better knowledge improves adherence to lifestyle changes and medication in patients with coronary heart disease. Eur. J. Cardiovasc. Nurs. 2004;3:321–330
  39. Van der Wal MH, Jaarsma T, Moser DK, Veeger NJ, van Gilst WH, van Veldhuisen DJ. Compliance in heart failure patients: the importance of knowledge and beliefs. Eur. Heart. J. 2006;27:434–440
  40. Vermeire E, Hearnshaw H, Van-Royen P, Denekens J. Patient adherence to treatment: three decades of research. A comprehensive review. J Clin. Pharm. Ther. 2001;26:331–342
  41. Weiss L, French T, Finkelstein R, Waters M, Mukherjee R, Agins B. HIV-related knowledge and adherence to HAART. AIDS-Care. 2003;15:673–679
  42. Grant RW, Devita NG, Singer DE, Meigs JB. Polypharmacy and medication adherence in patients with type 2 diabetes. Diabetes Care. 2003;26:1408–1412
  43. Bayly JR, Hollands RD, Riordan-Jones SE, et al. Prescribed vitamin D and calcium preparations in patients treated with bone remodelling agents in primary care: a report of a pilot study. Curr. Med. Res. Opin. 2006;22:131–137
  44. Sleath B, Wurst K, Lowery T. Drug information sources and antidepressant adherence. Community Ment. Health J. 2003;39:359–368

PII: S0378-5122(08)00197-7

doi: 10.1016/j.maturitas.2008.07.009

Maturitas
Volume 60, Issue 3 , Pages 223-229 , July 2008

Article Tools

* Image Usage & Resolution